Positive News Sentiment NASDAQ:PRTG Portage Biotech Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.72 +0.19 (+2.52%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$7.14▼$7.7650-Day Range$5.16▼$11.9552-Week Range$4.62▼$23.99Volume26,899 shsAverage Volume57,623 shsMarket Capitalization$103.06 millionP/E RatioN/ADividend YieldN/APrice Target$34.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Portage Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside343.7% Upside$34.25 Price TargetShort InterestHealthy3.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.11) to ($1.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.72 out of 5 starsMedical Sector807th out of 1,433 stocksCrude Petroleum & Natural Gas Industry63rd out of 127 stocks 3.5 Analyst's Opinion Consensus RatingPortage Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.25, Portage Biotech has a forecasted upside of 343.7% from its current price of $7.72.Amount of Analyst CoveragePortage Biotech has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.43% of the float of Portage Biotech has been sold short.Short Interest Ratio / Days to CoverPortage Biotech has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Portage Biotech has recently decreased by 11.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPortage Biotech does not currently pay a dividend.Dividend GrowthPortage Biotech does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTG. Previous Next 2.7 News and Social Media Coverage News SentimentPortage Biotech has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Portage Biotech insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 4.57% of the stock of Portage Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Portage Biotech are expected to decrease in the coming year, from ($1.11) to ($1.28) per share.Price to Book Value per Share RatioPortage Biotech has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address About Portage BiotechPortage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.Read More PRTG Stock News HeadlinesJune 6, 2022 | finance.yahoo.comPortage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 StudyApril 25, 2022 | finance.yahoo.comPortage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and StimunityApril 13, 2022 | finance.yahoo.comPortage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual MeetingMarch 31, 2022 | finance.yahoo.comPortage Biotech Provides Update on Clinical-Stage and Development ProgramsMarch 9, 2022 | finance.yahoo.comPortage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual MeetingFebruary 24, 2022 | finance.yahoo.comPortage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal YearFebruary 15, 2022 | finance.yahoo.comPortage Biotech Announces New Appointments to its Management Team and Board of DirectorsJanuary 24, 2022 | nasdaq.comPortage Biotech Inc. Common Stock (PRTG)January 5, 2022 | finance.yahoo.comPortage Biotech Announces Participation in January 2022 Investor ConferencesNovember 23, 2021 | finance.yahoo.comPortage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal YearNovember 22, 2021 | finance.yahoo.comPortage Biotech to Present at the Piper Sandler 33rd Annual Healthcare ConferenceNovember 15, 2021 | finance.yahoo.comPortage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics’ INT230-6 (PORT-1) at November Scientific ConferencesNovember 10, 2021 | finance.yahoo.comPortage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology TreatmentOctober 26, 2021 | finance.yahoo.com2 ‘Strong Buy’ Stocks Oppenheimer Predicts Will Surge at Least 50%October 8, 2021 | nasdaq.comPortage Rings the Opening BellSeptember 10, 2021 | finance.yahoo.comPortage Biotech Announces Participation in September 2021 Investor ConferencesAugust 30, 2021 | finance.yahoo.comPortage Biotech Announces Results for First Quarter of 2022 Fiscal YearAugust 12, 2021 | finance.yahoo.comPortage Biotech Issues Letter to ShareholdersAugust 5, 2021 | finance.yahoo.comPortage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)July 28, 2021 | finance.yahoo.comPortage Biotech Announces Results for Fiscal Year Ended March 31, 2021July 19, 2021 | marketwatch.comPortage Biotech CEO Interview Explains Why His Company Can Be Poised To Break Higher In 2H 2021 (NASDAQ: PRTG)June 29, 2021 | finance.yahoo.comPortage Biotech Added to Russell 2000(R) IndexJune 24, 2021 | benzinga.comMid-Afternoon Market Update: Dow Jumps Over 300 Points; Portage Biotech Shares SlideJune 24, 2021 | finance.yahoo.comPortage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary SharesJune 24, 2021 | marketwatch.comPortage Biotech Begins Public Offering of SharesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Crude petroleum & natural gas Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTG CUSIPN/A CIK1095435 Webwww.portagebiotech.com Phone416-929-1806FaxN/AEmployeesN/AYear FoundedN/ACompany Calendar Last Earnings11/22/2021Today7/07/2022Next Earnings (Estimated)8/29/2022Fiscal Year End3/31/2023Price Target and Rating Average Stock Price Forecast$34.25 High Stock Price Forecast$40.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+343.7%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.23% Return on Assets-11.46% Debt Debt-to-Equity RatioN/A Current Ratio41.31 Quick Ratio41.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.22 per share Price / Book0.63Miscellaneous Outstanding Shares13,350,000Free FloatN/AMarket Cap$103.06 million OptionableNot Optionable Beta0.82 Portage Biotech Frequently Asked Questions Should I buy or sell Portage Biotech stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Portage Biotech stock. View analyst ratings for Portage Biotech or view top-rated stocks. What is Portage Biotech's stock price forecast for 2022? 4 Wall Street research analysts have issued 12-month target prices for Portage Biotech's shares. Their PRTG stock forecasts range from $30.00 to $40.00. On average, they expect Portage Biotech's share price to reach $34.25 in the next twelve months. This suggests a possible upside of 343.7% from the stock's current price. View analysts' price targets for Portage Biotech or view top-rated stocks among Wall Street analysts. How has Portage Biotech's stock price performed in 2022? Portage Biotech's stock was trading at $10.73 at the beginning of the year. Since then, PRTG stock has decreased by 28.1% and is now trading at $7.72. View the best growth stocks for 2022 here. When is Portage Biotech's next earnings date? Portage Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 29th 2022. View our earnings forecast for Portage Biotech. How were Portage Biotech's earnings last quarter? Portage Biotech Inc. (NASDAQ:PRTG) posted its earnings results on Monday, November, 22nd. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. View Portage Biotech's earnings history. Who are Portage Biotech's key executives? Portage Biotech's management team includes the following people: Dr. Ian B. Walters M.B.A., M.D., CEO & Director (Age 54, Pay $568.5k)Mr. Allan J. Lee Shaw CPA, Chief Financial Officer (Age 58, Pay $209.95k)Mr. Steve Innaimo, VP of Project Management & OperationsDr. Robert A. Kramer Ph.D., Chief Scientific OfficerMr. Joseph Ciavarella, Chief Accounting OfficerMr. Brian Wiley, Chief Bus. Officer (Age 54) Who are some of Portage Biotech's key competitors? Some companies that are related to Portage Biotech include Gran Tierra Energy (GTE), VAALCO Energy (EGY), Goodrich Petroleum (GDP), Ring Energy (REI), Ring Energy (REI), Amplify Energy (AMPY), TransGlobe Energy (TGA), Evolution Petroleum (EPM), Camber Energy (CEI), Evolution Petroleum (EPM), PrimeEnergy Resources (PNRG), Alvopetro Energy (ALVOF), Battalion Oil (BATL), Epsilon Energy (EPSN) and VOC Energy Trust (VOC). View all of PRTG's competitors. What is Portage Biotech's stock symbol? Portage Biotech trades on the NASDAQ under the ticker symbol "PRTG." How do I buy shares of Portage Biotech? Shares of PRTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Portage Biotech's stock price today? One share of PRTG stock can currently be purchased for approximately $7.72. How much money does Portage Biotech make? Portage Biotech (NASDAQ:PRTG) has a market capitalization of $103.06 million. How can I contact Portage Biotech? Portage Biotech's mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The official website for Portage Biotech is www.portagebiotech.com. The company can be reached via phone at 416-929-1806. This page (NASDAQ:PRTG) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
